Browse
Explore conditions, clinical trials, and the organisations running them.
Never miss a new study
Get alerted when new trials match your condition
Sign up free to track the conditions you care about and get a personal digest when new trials appear.
By submitting, you agree to our Terms of use
116076 trials found · Page 21 of 5804
-
New triple therapy could extend lives in stomach cancer
Disease control Not yet recruitingGastric/GEJ adenocarcinomas are aggressive tumors with a high probability of death. Current treatment guidelines include two-drug cytotoxic chemotherapy with a fluoropyrimidine (mFOLFOX6: capecitabine or fluorouracil) and a platinum-based agent (CapOx: oxaliplatin or cisplatin). …
Phase: PHASE3 • Sponsor: Suzhou Transcenta Therapeutics Co., Ltd. • Aim: Disease control
Last updated Jun 27, 2026 08:04 UTC
-
Smartphone app aims to prevent strokes by catching silent atrial fibrillation
Prevention Recruiting nowThe Austrian Digital Heart Study is a population-based, siteless, randomized, controlled digital trial testing whether a smartphone-based atrial fibrillation screening and management pathway reduces stroke hospitalizations compared with usual care. Adults aged 65 years or older i…
Phase: NA • Sponsor: Medical University Innsbruck • Aim: Prevention
Last updated Jul 08, 2026 00:00 UTC
-
New drug aims to tame overactive thyroid in Graves' disease
Disease control Recruiting nowThe purpose of this study is to evaluate the efficacy and safety of BHV-1300 in adult participants with Graves' disease who are actively hyperthyroid
Phase: PHASE3 • Sponsor: Biohaven Therapeutics Ltd. • Aim: Disease control
Last updated Jul 25, 2026 00:00 UTC
-
New drug duo takes aim at hard-to-treat stomach cancer with liver metastases
Disease control Not yet recruitingThis study is a randomized, controlled, open-label phase III clinical trial, aims to compare the efficacy and safety of Retlirafusp alfa injection plus CAPOX versus the investigator's choice of anti-PD-1 antibody plus CAPOX as first-line treatment in patients with advanced gastri…
Phase: PHASE3 • Sponsor: Peking University • Aim: Disease control
Last updated Jul 02, 2026 00:00 UTC
-
Could a diabetes drug turn back the biological clock in HIV?
Disease control ENROLLING_BY_INVITATIONThis study is a pilot, open-lable, two-arm study. The investigators will enroll virally suppressed people living with HIV and obesity to evaluate the effect of tirzepatide on epigenetic aging, assessed by DNA methylation-based clocks using peripheral blood. In parallel, imaging s…
Phase: PHASE4 • Sponsor: National Taiwan University Clinical Trial Center • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
New drug cocktail aims to outperform standard immunotherapy in bile duct cancer
Disease control Recruiting nowTo compare overall survival (OS) of patients in Futibatinib and Zimberelimab in Combination with Gemcitabine plus Cisplatin versus Durvalumab or Pembrolizumab in Combination with Gemcitabine plus Cisplatin for patients with first-line advanced biliary tract cancer
Phase: PHASE3 • Sponsor: Taiho Pharmaceutical Co., Ltd. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
Engineered virus targets Hard-to-Treat cancers from the inside
Disease control Recruiting nowThe preclinical pharmacological mechanism of YH02 injection is well established. By constructing a vector expressing MMP13, introducing a human S promoter, and genetically modifying the capsid protein, the virus's permeability, tumor targeting capability, and infection efficiency…
Phase: PHASE2 • Sponsor: Tianjin First Central Hospital • Aim: Disease control
Last updated Jul 15, 2026 00:00 UTC
-
Gene therapy offers new hope for kids with brittle bone disease
Disease control Recruiting nowThis is a non-randomized, one-arm, open label, single-center, phase I/II, prospective study, to assess safety, feasibility and efficacy of FT024 in 8 children (Age: ≥ 28 days and ≤ 2 years old, Body weight: ≥ 4 kg) affected by ARO-1. Once written informed consent has been obtain…
Phase: PHASE1, PHASE2 • Sponsor: Fondazione Telethon • Aim: Disease control
Last updated Jun 27, 2026 14:02 UTC
-
New hope for KRAS lung cancer: targeted pill plus immunotherapy in Late-Stage trial
Disease control Recruiting nowResearchers are looking for new ways to treat locally advanced non-small cell lung cancer (NSCLC) that is unresected and has a gene mutation called KRAS G12C. Researchers want to learn if calderasib (MK-1084) can be given with durvalumab, an immunotherapy, to treat NSCLC after ch…
Phase: PHASE3 • Sponsor: Merck Sharp & Dohme LLC • Aim: Disease control
Last updated Jul 22, 2026 00:00 UTC
-
Pioneering fetal surgery aims to save babies born with a hole in their diaphragm
Disease control Recruiting nowThe purpose of the study is to determine if babies with left or right-sided CDH that undergo the FETO procedure survive more often and have fewer long-term complications than babies that have similar left or right-sided CDH that elect not to have the FETO procedure performed duri…
Phase: NA • Sponsor: Dr Erin Perrone • Aim: Disease control
Last updated Jul 01, 2026 00:00 UTC
-
New pill targets tough pancreatic cancer mutation
Disease control Recruiting nowThis study will assess the safety and efficacy of VS-7375 alone and in combination with cetuximab in patients with metastatic KRAS G12D - mutated Pancreatic Cancer
Phase: PHASE2 • Sponsor: Verastem, Inc. • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New combo pill aims to shrink spleens and ease symptoms in bone marrow cancer
Disease control Recruiting nowThe purpose of this trial is to evaluate whether treatment with pelabresib in combination with ruxolitinib leads to improved clinical outcomes compared to ruxolitinib alone in patients with primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), or post-essent…
Phase: PHASE3 • Sponsor: Novartis Pharmaceuticals • Aim: Disease control
Last updated Jul 19, 2026 00:00 UTC
-
New pill could cure parasitic skin disease in months
⭐️ CURE ⭐️ Not yet recruitingThe purpose of this clinical trial is to measure efficacy, safety and pharmacokinetics (PK) of two LXE408 oral regimens and oral miltefosine tablets as active control in localized cutaneous leishmaniasis in the region of the Americas (AMR), and assess its suitability for use in m…
Phase: PHASE2 • Sponsor: Drugs for Neglected Diseases • Aim: ⭐️ CURE ⭐️
Last updated Jun 27, 2026 12:29 UTC
-
Texts to parents may prevent teen suicide after ER visit
Disease control Recruiting nowThe goal of the study is to determine effectiveness of a behaviorally informed text messaging intervention to help parents increase safety practices and reduce their teens' access to lethal means following a suicide-related emergency department visit.
Phase: NA • Sponsor: University of Texas Southwestern Medical Center • Aim: Disease control
Last updated Jun 27, 2026 13:01 UTC
-
Engineered virus plus immunotherapy aims to outperform chemo in advanced lung cancer
Disease control Recruiting nowThis phase III trial compares the effect of the combination of aglatimagene besadenovec and pembrolizumab versus standard of care docetaxel chemotherapy for the treatment of stage IV non-squamous, non-small cell lung cancer. Aglatimagene besadenovec is a replication-deficient ade…
Phase: PHASE3 • Sponsor: Candel Therapeutics, Inc. • Aim: Disease control
Last updated Jun 27, 2026 14:01 UTC
-
Could chemoradiotherapy replace surgery for esophageal cancer?
Disease control Not yet recruitingThis is a Phase III, multicenter, open-label, randomized controlled trial. The study aims to compare organ preservation versus esophagectomy in patients with locally advanced, resectable thoracic esophageal squamous cell carcinoma (ESCC) who achieve a complete or partial clinical…
Phase: PHASE3 • Sponsor: Henan Cancer Hospital • Aim: Disease control
Last updated Jun 27, 2026 13:06 UTC
-
Gene therapy could free Wilson's patients from daily pills
Disease control Not yet recruitingThis is a multicenter, open-label, single-arm, single-dose Phase I/II clinical study. It aims to evaluate the safety, tolerability, efficacy, immunogenicity, pharmacodynamic (PD) and pharmacokinetic (PK) profiles of LY-M003 Injection in patients with Wilson's Disease (WD).
Phase: PHASE1, PHASE2 • Sponsor: Lingyi Biotech Co., Ltd. • Aim: Disease control
Last updated Jul 04, 2026 00:00 UTC
-
Immunotherapy cocktail aims to turn untreatable stomach tumors into surgical targets
Disease control Not yet recruitingThis study was a prospective, single-arm, multi-center, phase Ⅱ clinical study to investigate the efficacy and safety of ipilimumab injection N01 combined with sintilimab and modified XELOX conversion therapy in patients with unresectable locally advanced gastric cancer who had n…
Phase: PHASE2 • Sponsor: Chen Lizhu • Aim: Disease control
Last updated Jun 27, 2026 13:07 UTC
-
Immunotherapy may let some GI cancer patients skip the knife
Disease control Not yet recruitingThis is a single-center, bidirectional (retrospective and prospective) registry study aimed at evaluating the safety and efficacy of Non-Operative Management (NOM) and Organ-Preserving Functional Surgery (OPFS) in patients with mismatch repair-deficient/microsatellite instability…
Sponsor: Peking University Cancer Hospital & Institute • Aim: Disease control
Last updated Jun 27, 2026 14:00 UTC
-
New combo treatment could help more Large-Stroke patients walk again
Disease control Not yet recruitingStroke is a frequent and severe disease worldwide, representing the second leading cause of death and the leading cause of acquired disability. Over the last thirty years, reperfusion therapies have transformed the prognosis of ischemic stroke. For patients with acute ischemic st…
Phase: PHASE3 • Sponsor: Assistance Publique - Hôpitaux de Paris • Aim: Disease control
Last updated Jun 27, 2026 12:36 UTC